Targeted therapies articles from across Nature Portfolio

A targeted therapy is one that has been developed to affect a specific target, such as an enzyme or receptor. Targeted therapies can either block or increase the function of their target in order to treat a given disease; in this case, cancer.

Featured

News & Views | 16 March 2023

A synthetic tumour microenvironment
- Akhilesh K. Gaharwar
- & Irtisha Singh
Nature Materials, 1-2

Latest Research and Reviews

Research
22 March 2023 | Open Access

IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis

Glioblastoma stem-like cells (GSCs) contribute to therapeutic resistance and recurrence of glioblastomas. Here the authors show that Insulin-like Growth Factor-Binding Protein 5 (IGFBP5) is a ligand for Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) promotes GSCs invasion.
- Weiwei Lin
- , Rui Niu
- & Jinlong Yin
Nature Communications 14, 1578
Research
20 March 2023 | Open Access

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer
- Michèle Beniey
- , Audrey Hubert
- & Saima Hassan
British Journal of Cancer, 1-12
Research
18 March 2023 | Open Access

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

Genomic instability occurs infrequently in in diffuse large B cell lymphoma (DLBCL), suggesting a therapeutic vulnerability. Here, the authors identify a synergistic combination between the induction of polyploidy by a PLK4 inhibitor and a BCL-2 inhibitor in DLBCL.
- Ana Portelinha
- , Mariana da Silva Ferreira
- & Hans-Guido Wendel
Nature Communications 14, 1522
Research
17 March 2023 | Open Access

Spectrum of BRCA1 interacting helicase 1 aberrations and potential prognostic and therapeutic implication: a pan cancer analysis
- Guo Long
- , Kuan Hu
- & Juanni Li
Scientific Reports 13, 4435
Research
17 March 2023 | Open Access

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies

Hypomethylating agents, such as 5-Azacytidine (5-AZA), are standard of care for patients with myelodysplastic and myeloid malignancies, however response rates are limited and risk of relapses high. Here the authors show that inhibition of lysyl oxidases synergizes with 5-AZA to improve erythropoiesis and reduce disease burden in myelodysplastic neoplasms models.
- Qingyu Xu
- , Alexander Streuer
- & Daniel Nowak
Nature Communications 14, 1497
Research
17 March 2023 | Open Access

Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer
- Elien Heylen
- , Paulien Verstraete
- & Kim R. Kampen
British Journal of Cancer, 1-17

All Research & Reviews

News and Comment

Research Highlights | 16 March 2023

Rucaparib improves PFS in patients with BRCA1/2-altered mCRPC
- Louise Stone
Nature Reviews Urology, 1
News & Views | 16 March 2023

A synthetic tumour microenvironment

A bioengineered model incorporating a synthetic extracellular matrix recapitulates the lymphoid tumour microenvironment, making it a valuable tool for drug testing and designing personalized therapies.
- Akhilesh K. Gaharwar
- & Irtisha Singh
Nature Materials, 1-2
Editorial
15 March 2023 | Open Access

Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
- Anushka Walia
- & Vinay Prasad
Blood Cancer Journal 13, 36
Research Highlights | 14 March 2023

PI5P4Kα: a target in prostate cancer?
- Louise Stone
Nature Reviews Urology, 1
Research Highlights | 16 February 2023

A biomarker-driven therapy for ovarian cancer

An antibody–drug conjugate showed impressive anti-cancer activity in selected patients with platinum-resistant ovarian cancer, and could become a new standard of care.
- Karen O’Leary
Nature Medicine
News & Views | 02 February 2023

Master kinases extracted from proteogenomic networks in glioblastoma drive cancer subtypes

Using an unbiased algorithm based on kinase–phosphorylation site interactions that is applicable to any proteomic dataset, we identified and experimentally validated two protein kinases (PKCδ and DNA-PKcs) as the master kinases that drive two functional subtypes of glioblastoma multiforme and are potential therapeutic targets of other cancer subtypes.

Nature Cancer 4, 159-160

All News & Comment

Targeted therapies articles from across Nature Portfolio

Featured

A synthetic tumour microenvironment

Latest Research and Reviews

IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

Spectrum of BRCA1 interacting helicase 1 aberrations and potential prognostic and therapeutic implication: a pan cancer analysis

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies

Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer

News and Comment

Rucaparib improves PFS in patients with BRCA1/2-altered mCRPC

A synthetic tumour microenvironment

Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm

PI5P4Kα: a target in prostate cancer?

A biomarker-driven therapy for ovarian cancer

Master kinases extracted from proteogenomic networks in glioblastoma drive cancer subtypes

Search

Quick links